Surgery Partners (SGRY) Q2 2025: Orthopedic Joint Procedures Surge 26% as De Novo Pipeline Expands

2025-08-05 | By EarningsIQ Research

Surgery Partners’ Q2 revealed a business doubling down on high-acuity orthopedics and de novo facility growth, even as M&A deployment lagged initial targets. Leadership’s post-strategic review clarity is translating into a sharpened focus on asset optimization, cash flow acceleration, and disciplined capital allocation. Guidance holds, but investors should watch for timing-driven mix shifts and ongoing leverage reduction efforts as the company leans into ASC tailwinds.

Summary

• Orthopedic Expansion Accelerates: Total joint procedures jumped 26%, reinforcing the shift to higher-acuity cases.
• De Novo Growth as Margin Lever: New facility openings and pipeline point to lower-cost, higher-margin expansion over traditional M&A.
• Portfolio Optimization in Focus: Asset sales and partnerships are on the table to expedite deleveraging and cash flow growth.

Performance Analysis

Surgery Partners delivered Q2 revenue and adjusted EBITDA in line with expectations, with net revenue up just under 8.5% and adjusted EBITDA up 9% year over year. Same facility revenue growth reached over 5%, split between 3.4% case growth and 1.6% rate growth, demonstrating balanced momentum. Orthopedics was the standout, with total joint procedures up 26% as the company leverages its 69 surgical robots and targeted physician recruitment to capture higher-acuity volumes. Gastrointestinal and musculoskeletal (MSK) procedures also contributed to the case mix improvement.

Margin expansion was modest but positive, as disciplined cost management and integration synergies offset some inflationary and professional fee pressures. Operating cash flow improved, with day sales outstanding (DSO) reduced by three days sequentially, and liquidity remains ample at $645 million. However, interest expense rose $23 million due to the expiration of interest rate swaps, now replaced by a cap, putting a ceiling on variable debt costs.

• Case Mix Shift: Higher-acuity orthopedic and GI volumes drove revenue and margin improvement.
• De Novo Ramp: Of 20 facilities opened since 2022, 12 are now profitable, with 10 more under construction.
• M&A Timing Drag: Only $66 million deployed YTD versus a $200 million annual target, pushing some earnings contribution into future periods.

Guidance was reiterated for both revenue and adjusted EBITDA, but management signaled results may come in at the lower end of the range due to the slower pace of acquisitions.

Executive Commentary

Strategic Positioning

1. High-Acuity Orthopedics and Robotics

Surgery Partners is capitalizing on migration of complex orthopedic procedures to ambulatory surgery centers (ASCs), with 80% of facilities capable of higher-acuity orthopedics and nearly half performing total joint replacements. Investment in 69 surgical robots enables more complex procedures and supports physician recruitment, creating a virtuous cycle of higher case volume and rate growth.

2. De Novo Facility Expansion

De novo facilities, newly constructed and purpose-built ASCs, are increasingly central to the company’s growth. These assets have lower effective multiples than traditional acquisitions and are heavily weighted toward high-acuity specialties. Of the 20 opened since 2022, 12 have reached profitability, and 10 more are under construction. This pipeline provides a cost-effective, margin-accretive growth lever as ramping facilities move toward full earnings contribution.

3. Portfolio Optimization and Asset Monetization

Following the strategic review, leadership is proactively evaluating asset sales and partnerships, particularly with health systems, to accelerate deleveraging and cash flow. Non-core facilities and markets may be divested or restructured, with proceeds redeployed toward core ASC service lines and self-funding future growth. This marks a shift toward a more focused, capital-efficient operating model.

4. Disciplined M&A and Capital Allocation

While the M&A pipeline remains robust, management is prioritizing quality and fit over pace, reiterating a $200 million annual target but acknowledging timing variability. Recent acquisitions were completed at effective multiples below eight times adjusted EBITDA, with integration expected to lower multiples further. The company’s liquidity position supports ongoing M&A without near-term capital market dependence.

5. Regulatory and Reimbursement Tailwinds

Minimal exposure to Medicaid and health exchange reimbursement insulates SGRY from near-term regulatory risk. CMS proposals to expand ASC covered procedures and phase out the inpatient-only list are viewed as incremental tailwinds, enabling more complex cases to shift to the outpatient setting and supporting long-term market growth projections.

Key Considerations

Q2 marked a period of operational consistency and strategic reorientation, with clear signals that SGRY is leaning into its strengths in high-acuity outpatient surgery and disciplined capital deployment.

Key Considerations:

• Orthopedic and Robotics Leverage: Expanded robotics footprint and orthopedic focus are driving both volume and rate gains.
• De Novo Margin Upside: New facility ramping provides lower-cost, scalable growth with margin expansion potential as more sites reach profitability.
• Portfolio Optimization Levers: Asset sales and system partnerships could accelerate deleveraging and enhance cash flow, supporting self-funded growth.
• M&A Pace and Earnings Timing: Slower deployment in H1 may limit near-term EBITDA, but pipeline remains strong for H2 and beyond.
• Interest Expense Headwind: Swap expiration increased interest costs, but floating rate exposure is now capped, limiting further risk.

Risks

Timing risk around M&A and de novo ramp may create near-term earnings variability, especially if transaction closing or facility openings slip. Interest expense remains elevated post-swap expiration, and while capped, could pressure cash flow if rates rise. Regulatory shifts, while currently favorable, require ongoing monitoring, and portfolio optimization may introduce execution risk as assets are divested or restructured.

Forward Outlook

For Q3 2025, Surgery Partners guided to:

• Revenue and adjusted EBITDA in line with the full-year range, with results likely at the lower end due to M&A timing.
• Continued margin expansion and balanced same facility growth between volume and rate.

For full-year 2025, management reiterated guidance:

• Revenue of $3.3 to $3.45 billion
• Adjusted EBITDA of $555 to $565 million

Management emphasized robust pipeline visibility for both acquisitions and de novo development, and signaled an investor day later this year to detail long-term strategy and growth plans.

• Visibility into higher-acuity case migration and ASC reimbursement policy tailwinds
• Focus on cash flow conversion and leverage reduction through asset optimization

Takeaways

SGRY’s Q2 performance underscores a business leaning into high-acuity ASC trends and operational discipline, even as near-term M&A pacing tempers guidance confidence.

• Orthopedic and De Novo Growth: Purpose-built, higher-acuity facilities and robotics investments are driving volume and revenue mix improvement.
• Portfolio Optimization and Cash Flow: Asset sales and system partnerships are now core levers for accelerating deleveraging and self-funding growth.
• Watch for Ramp Timing: H2 results will hinge on M&A closing cadence and de novo ramp; investors should monitor execution and asset sale progress.

Conclusion

Surgery Partners is methodically positioning itself as the leading independent short-stay surgical platform, with a focus on higher-acuity cases, disciplined capital allocation, and asset optimization. Execution on de novo ramp and portfolio actions will determine the pace of deleveraging and margin expansion into 2026.

Industry Read-Through

SGRY’s results reinforce the ongoing migration of complex surgical procedures from hospitals to ASCs, especially in orthopedics, as technology and payer incentives align. Robotics adoption and physician alignment are becoming critical differentiators for outpatient surgery platforms. Regulatory momentum around site neutrality and ASC procedure expansion provides tailwinds for operators with scale and high-acuity capabilities. Portfolio optimization and asset monetization are increasingly in focus as platforms seek to accelerate deleveraging and self-funded growth, a trend likely to be echoed across the sector.

SGRY Healthcare Ambulatory Surgery Centers Orthopedics De Novo M&A Robotics Asset Optimization